Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Amortizatization of Intangibles (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Amortizatization of Intangibles for 15 consecutive years, with $9.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortizatization of Intangibles fell 58.72% year-over-year to $9.7 million, compared with a TTM value of $12.7 million through Dec 2025, down 51.53%, and an annual FY2025 reading of $12.7 million, down 51.53% over the prior year.
  • Amortizatization of Intangibles was $9.7 million for Q4 2025 at Neurocrine Biosciences, up from -$11.3 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $23.5 million in Q4 2024 and bottomed at -$11.4 million in Q3 2024.
  • Average Amortizatization of Intangibles over 4 years is $4.7 million, with a median of $6.3 million recorded in 2023.
  • Peak annual rise in Amortizatization of Intangibles hit 2433.33% in 2024, while the deepest fall reached 211.76% in 2024.
  • Year by year, Amortizatization of Intangibles stood at $3.9 million in 2021, then skyrocketed by 61.54% to $6.3 million in 2023, then surged by 273.02% to $23.5 million in 2024, then crashed by 58.72% to $9.7 million in 2025.
  • Business Quant data shows Amortizatization of Intangibles for NBIX at $9.7 million in Q4 2025, -$11.3 million in Q3 2025, and $13.3 million in Q2 2025.